Danaher (NYSE:DHR) and OncoCyte (NASDAQ:OCX) Financial Survey

Danaher (NYSE:DHR) and OncoCyte (NASDAQ:OCX) are both multi-sector conglomerates companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

79.1% of Danaher shares are owned by institutional investors. Comparatively, 55.4% of OncoCyte shares are owned by institutional investors. 10.9% of Danaher shares are owned by insiders. Comparatively, 1.9% of OncoCyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Danaher and OncoCyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Danaher	17.26%	12.25%	7.43%
OncoCyte	-3,923.58%	-77.26%	-33.66%

Valuation & Earnings

This table compares Danaher and OncoCyte’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Danaher	$23.89 billion	7.45	$4.76 billion	$6.39	37.61
OncoCyte	$1.50 million	15.14	-$27.78 million	N/A	N/A

Danaher has higher revenue and earnings than OncoCyte.

Volatility & Risk

Danaher has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Danaher and OncoCyte, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Danaher	0	6	9	0	2.60
OncoCyte	0	1	2	0	2.67

Danaher currently has a consensus price target of $267.43, suggesting a potential upside of 11.27%. OncoCyte has a consensus price target of $3.87, suggesting a potential upside of 40.61%. Given OncoCyte’s stronger consensus rating and higher probable upside, analysts plainly believe OncoCyte is more favorable than Danaher.

Summary

Danaher beats OncoCyte on 9 of the 12 factors compared between the two stocks.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.